Pharmaceutical company Novo Nordisk (NYSE:NVO) is taking legal action to prevent the sale of knockoff versions of its semaglutide drugs in the U.S., citing trademark infringement and violation of state regulations against untested medications. The company argues that these knockoffs pose a risk to patient safety and provide an unfair competitive advantage. Despite warnings, some patients continue to use the knockoffs due to high drug prices.